Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

David Pfister; Natalia Fernández Núñez; Anindita Sinha; Assaf Weiner; Aleksandra Deczkowska; Matthias Pinter; Olivier Govaere; Felicitas Müller; Quentin M. Anstee; T Entgleitner; Roland Rad; Roser Pinyol; Sara Torrecilla; Michael Dudek; Percy A. Knolle; Amy Weber; D Lengenhagger; Josep M. Llovet; Ido Amit; Felix Meissner; Burkhard Becher; Mathias Heikenwälder

doi:10.1055/a-1143-8420

Related publications

Article2020

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

D Pfister, Nicole N Nunez, A Sinha, Assaf Weiner, A Deckowska, Matthias Pinter, Olivier Govaere, F Müller, Quentin M. Anstee, T Entgleitner, Roland Rad, Roser Pinyol, Sara Torrecilla, M Dudek, P Knolle, Angelika Weber, D Lengenhagger, Josep M. Llovet, Ido Amit, F Meissner, B Becher, M Heikenwälder

Zeitschrift für Gastroenterologie

Article2018

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen Jardine, Georgia Kirn, John C. Bell, Michael W. McBurney, David H Raulet, Michele Ardolino

Article2021

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner, Florian L. Müller, Ankit Sinha, Ekaterina Friebel, Thomas Engleitner, Daniela Lenggenhager, Anja Moncsek, Danijela Heide, Kristin Stirm, Jan Kosla, Eleni Kotsiliti, Valentina Leone, Michael Dudek, Suhail Yousuf, Donato Inverso, Indrabahadur Singh,

Article2020

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Masatoshi Kudo

Editorial Material2022

Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy

Mélanie Bourgin, Oliver Kepp, Guido Guido Kroemer

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

Abstract

Discussion(0)

Related publications

Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy